Novo Nordisk

← The SEC Ephemeris: the whole map

Novo Nordisk NNC0148-0287

In the graph: all 2 documents (15 pages).

Application: BLA 761326
Ticker: Novo Nordisk
Product: NNC0148-0287
Disease area: Not yet classified
Response path: Not yet classified
Complete Response Letters: July 10, 2024 · April 24, 2023

From FDA letters and SEC filings. Not investment or medical advice.

Not yet classified

MediWound, Ltd. “concentrate of proteolytic enzymes enriched
MEDRx USA, Inc.
Meitheal Pharmaceuticals Inc. fosfomycin
Merck & Co., Inc. Suvorexant
Mesoblast, Inc. remestemcel-L manufactured at your Singapore location
Metacel Pharmaceuticals, LLC Ozobax
Milestone Pharmaceuticals USA, Inc. etripamil
Minerva Neurosciences, Inc roluperidone
Mylan GmbH insulin glargine
Mylan Pharmaceuticals Inc. the following drug product: > Abacavir
Mylan Pharmaceuticals Inc., a Viatris Company the following drug product: > Abacavir
Nanocopoeia, LLC this action
NeuroDerm, Ltd. carbidopa levodopa
Nevakar, Inc. Norepinephrine Bitartrate
nnoPharma Licensing LLC Acetaminophen njection
Nobelpharma Co., Ltd. sirolimus
NorthStar Medical Radioisotopes, LLC TechneGen Generator
Novartis Pharmaceuticals Corporation inclisiran
Novitium Pharma LLC Hydroxychloroquine Sulfate
Novo Nordisk NNC0148-0287
Ocular Therapeutix, Inc. DEXTENZA
Ocuvex Therapeutics, Inc. brimonidine tartrate
Omeros Corporation OMS721
Orexo AB Naloxone hydrochloride
Organon, Inc. Gepirone hydrochloride
Orphan Therapeutics, LLC Lucassin
Orphazyme A/S arimoclomol
Otsuka Pharmaceutical Company, Ltd. ABILIFY MAINTENA
OWP Pharmaceuticals, Inc. this action
Par Sterile Products, LLC Micafungin
Pfizer Inc. Trazimera
Pfizer Ireland Pharmaceuticals MOD-4023
AB Pharmaceuticals, LLC the following drug product: > Efavirenz
PharmaEssentia Corporation P1101
Pharmaxis Ltd. Bronchitol
Phathom Pharmaceuticals, Inc. Voquezna
Pierre Fabre Pharmaceuticals Inc. tabelecleucel®
Polarean Inc. Xenoview
Provention Bio, Inc. PRV-031

All 283 on the full map →

Group by

Build queue · replay at pipeline speed